Intra-Cellular Therapies Inc. (NASDAQ:ITCI) headquartered in New York, will host a conference call for the investment community to discuss the 3Q20 earnings result on 9th November 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.intracellulartherapies.com
Earnings Expectation
Intra-Cellular Therapies Inc. is expected to report third quarter earnings results, before market open, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1 per share from revenue of $ 5.86 million. Looking ahead, the full year loss are expected at $ 3.56 per share on the revenues of $ 20.92 million.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinsons disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety.
